MedTrace Logo

A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease

NCT00665223 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 437

Last updated 2023-08-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.

Conditions

Interventions

DRUG

ACR16

Capsules will be swallowed whole with water.

DRUG

Placebo

Capsules will be swallowed whole with water.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Teva Medical Expert, MD · Teva Branded Pharmaceutical Products R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-24
Primary Completion
2010-06-14
Completion
2010-06-14

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665223 on ClinicalTrials.gov